What we do Themis Medicare Ltd manufactures pharmaceutical formulations and synthetic active pharmaceutical ingredients, focusing on anti-tuberculosis and hospital segment therapies. |
Founded in 1,969 |
Market share Ranked 4th in anti-tuberculosis drugs with exports to 44+ countries, strong domestic hospital business. |
Problem solved Provides essential medicines for tuberculosis and critical care, addressing healthcare needs domestically and globally. |
Top clients or who we serve Hospitals, healthcare providers, pharmaceutical distributors; B2B and B2C segments primarily within India and export markets. |
Key management Dr. Sachin D. Patel, Managing Director & CEO; Dr. Dinesh S. Patel, Chairman. |
Our journey and innovations Started in 1969, evolved from chemical manufacturing to pharma; launched novel drugs, expanded global exports, and diversified hospital services. |
Where we operate India (plants in Vapi, Haridwar, Hyderabad) and exports to over 44 countries including Europe and Asia. |
Top products or what we offer Anti-tuberculosis drugs, hospital division injectables, cardiac and muscular relaxants, and novel drug delivery systems like Lenzetto. |
Top brands Lenzetto (estradiol delivery), Themiseal (haemostatic antimicrobial), and various anti-TB formulations. |
Raw materials needed Chemical intermediates for APIs, pharmaceutical excipients for formulations. |
Raw materials supplier Not specifically disclosed; likely sourced from chemical raw material suppliers domestically and internationally. |
Recurring vs cyclical contribution Revenue primarily recurring from pharmaceutical sales with moderate cyclical impacts due to regulatory and market conditions. |
Our industry position Leader in tuberculosis medication with growing presence in hospital injectable market and diversified pharmaceutical segments. |
Financial highlights Revenue Rs. 410 Cr in 2024-25; PAT Rs. 23.9 Cr; 6% revenue growth; focused on margin improvement and cost rationalization. |
Geographical revenue split Approximately 82% of revenue from India and 18% from international markets. |
Order book - |
Whats driving growth Growth supported by hospital business expansion, new injectable product launches, and doubled API business despite certain market disruptions. |
Our future plans Focus on consolidating hospital business leadership in India, product innovation, and international market expansion. |
Our green promise Initiatives in energy conservation, shift to environmentally friendly fuels, and investment in LED lighting for manufacturing units. |
Our people and values Over 1,400 employees including PhDs and masters degree holders, with emphasis on compliance, governance, and employee development. |
Key challenges ahead Regulatory scrutiny on formulations, market disruptions, and competitive pressure in domestic and export markets. |
Interesting facts One of few Indian pharma firms with EU GMP certifications and long-standing collaborations across 44+ countries. |
Risks and strategy Risks include regulatory changes and market competition; strategy involves R&D-led innovation, cost control, and focusing on hospital business. |
